Literature DB >> 15081262

Microarray detection of E2F pathway activation and other targets in multiple sclerosis peripheral blood mononuclear cells.

Antonio H Iglesias1, Sandra Camelo, Daehee Hwang, Raul Villanueva, George Stephanopoulos, Fernando Dangond.   

Abstract

We performed microarray analysis of peripheral blood mononuclear cells (PBMCs) from multiple sclerosis (MS) patients and detected a profile of immune cell activation, autoantigen upregulation, and enhanced E2F pathway transcription. Accordingly, E2f1-deficient mice manifested only mild disability upon induction of experimental autoimmune encephalomyelitis (EAE). Furthermore, PBMCs from Avonex-treated patients had lower expression of E2F targets. The profile was enriched in genes known to harbor MS-associated polymorphisms, or localized to MS susceptibility chromosomal regions. Our study shows that PBMC microarrays reflect MS pathobiology that can be validated in the EAE model.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15081262     DOI: 10.1016/j.jneuroim.2004.01.017

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  15 in total

1.  Integration of MicroRNA databases to study MicroRNAs associated with multiple sclerosis.

Authors:  Charlotte Angerstein; Michael Hecker; Brigitte Katrin Paap; Dirk Koczan; Madhan Thamilarasan; Hans-Jürgen Thiesen; Uwe Klaus Zettl
Journal:  Mol Neurobiol       Date:  2012-05-02       Impact factor: 5.590

2.  Neuropilin-1 is a direct target of the transcription factor E2F1 during cerebral ischemia-induced neuronal death in vivo.

Authors:  Susan X Jiang; Melissa Sheldrick; Angele Desbois; Jacqueline Slinn; Sheng T Hou
Journal:  Mol Cell Biol       Date:  2006-12-18       Impact factor: 4.272

3.  E2F1: a potential therapeutic target for systematic lupus erythematosus.

Authors:  Xin-Yu Fang; Dong-Qing Ye
Journal:  Rheumatol Int       Date:  2013-09-27       Impact factor: 2.631

4.  Blood RNA profiling in a large cohort of multiple sclerosis patients and healthy controls.

Authors:  Dorothee Nickles; Hsuan P Chen; Michael M Li; Pouya Khankhanian; Lohith Madireddy; Stacy J Caillier; Adam Santaniello; Bruce A C Cree; Daniel Pelletier; Stephen L Hauser; Jorge R Oksenberg; Sergio E Baranzini
Journal:  Hum Mol Genet       Date:  2013-06-06       Impact factor: 6.150

5.  Gene expression changes in multiple sclerosis relapse suggest activation of T and non-T cells.

Authors:  J William Lindsey; Sandeep K Agarwal; Filemon K Tan
Journal:  Mol Med       Date:  2010-09-17       Impact factor: 6.354

Review 6.  A genomic approach to human autoimmune diseases.

Authors:  Virginia Pascual; Damien Chaussabel; Jacques Banchereau
Journal:  Annu Rev Immunol       Date:  2010       Impact factor: 28.527

7.  Peripheral blood mononuclear cell gene expression in chronic obstructive pulmonary disease.

Authors:  Timothy M Bahr; Grant J Hughes; Michael Armstrong; Rick Reisdorph; Christopher D Coldren; Michael G Edwards; Christina Schnell; Ross Kedl; Daniel J LaFlamme; Nichole Reisdorph; Katerina J Kechris; Russell P Bowler
Journal:  Am J Respir Cell Mol Biol       Date:  2013-08       Impact factor: 6.914

8.  Gene expression studies in multiple sclerosis.

Authors:  Lotti Tajouri; Francesca Fernandez; Lyn R Griffiths
Journal:  Curr Genomics       Date:  2007-05       Impact factor: 2.236

Review 9.  Monitoring of multiple sclerosis immunotherapy: from single candidates to biomarker networks.

Authors:  Robert H Goertsches; Michael Hecker; Uwe K Zettl
Journal:  J Neurol       Date:  2008-12       Impact factor: 4.849

10.  Identification of a novel risk locus for multiple sclerosis at 13q31.3 by a pooled genome-wide scan of 500,000 single nucleotide polymorphisms.

Authors:  Manuel Comabella; David W Craig; Montse Camiña-Tato; Carlos Morcillo; Cristina Lopez; Arcadi Navarro; Jordi Rio; Xavier Montalban; Roland Martin
Journal:  PLoS One       Date:  2008-10-22       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.